Run the same gene panel against two disease contexts. See where drug candidates overlap, pathways diverge, and evidence differs.
Drugs that rank Tier I or II in both disease contexts — the most translatable candidates for cross-indication repurposing.
Drugs that rank high in Disease A only, or Disease B only — revealing where biology or evidence diverges.
Pathways significant in A but not B, and vice versa — showing where the same genes drive different biology in each context.
Where evidence quality differs most between the two contexts — citation coverage, grounding rate, and drug candidate depth compared side by side.